James Berenson, MD, Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, shares his perspectives on future developments in managing multiple myeloma. The approval of multiple novel treatments have increased the number of treatment options for patients, and further research will be required to improve efficacy and reduce toxicity. Patient response to treatment will additionally be more accurately assessed with the development of new markers to detect solubilized B cell maturation antigen (BCMA). This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.